# MASTER-2 (NCT05231629)

> Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05231629
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Alabama at Birmingham
- Conditions: Multiple Myeloma
- Interventions: Dara-VRd intensification, Dara-R maintenance; AHCT intensification, Dara-R maintenance; AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance; AHCT intensification, Dara-R consolidation, Dara-R maintenance; Dara-VRd induction
- Enrollment: 300
- Primary outcome: Depth of response obtained with 6 cycles of Dara-VRd
- Primary outcome: Sustained MRD negativity

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 34
- YouTube: 7
- Podcasts: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=master-2-nct05231629

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05231629", "email": "<work email>"}; the inbox owner confirms by the emailed link.